© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Peramivir trihydrate emerged from the urgent global quest to overcome influenza viruses. Japanese researchers working for BioCryst Pharmaceuticals teamed up with Shionogi & Co. in the 1990s. After a few dead ends and shelved molecules, Peramivir surfaced as a frontrunner. The original push came from a simple yet pressing question: how do we stop rapidly mutating flu viruses when earlier antivirals started failing? Scientists understood that the flu’s neuraminidase enzyme made viral replication possible. With zanamivir and oseltamivir already in the game, peramivir offered a new way forward by clamping down on neuraminidase through a different structure. Approval in Japan came in 2010, then in the United States by 2014, making it one of the main options when flu season spikes or in cases where patients can’t take oral medications.
Peramivir trihydrate gets recognized as an injectable antiviral for people battling acute, uncomplicated influenza. Designed for intravenous use, it works especially well in settings where quick, potent action counts most—think emergency departments or when pills aren’t an option. As a trade-off for oral convenience, the intravenous route provides assurance that the active drug reaches the bloodstream fast, giving doctors a tool for severe infections and people who can't swallow medicines.
This compound shows up as a white powder, easy to dissolve in water thanks to its trihydrate form. The chemical formula is C15H28N4O11, with a molecular weight sitting around 410 grams per mole. The molecule’s backbone blends cyclopentane, carboxyl, guanidine, and acetamido groups, allowing it to mimic part of the flu neuraminidase enzyme’s natural substrate. The water molecules in its trihydrate form help keep it stable at room temperature, offering shelf life and ease of handling for hospital pharmacists.
Manufacturers typically deliver peramivir trihydrate as a sterile, lyophilized powder for reconstitution, but some hospitals receive pre-mixed solutions for time savings. Labels always spell out concentrations, storage instructions, and warnings, particularly for those with known hypersensitivities. The FDA mandates batch numbers, expiry dates, and specifics about allowable temperatures. Every vial also identifies the required diluents and contains clear barcodes for inventory tracking, so mistakes on the hospital floor drop significantly.
Synthesis starts with a cyclopentene carboxylate, followed by a careful sequence of amination, esterification, and guanidination reactions. Key intermediates take shape through liquid-phase chemistry, where temperature and pH control dictate yield and byproduct formation. Chemists then isolate the principal product through column chromatography or crystallization, convert it to the trihydrate, and vacuum-dry the powder for medical use. The trihydrate form, resulting from hydration under controlled humidity, stabilizes the active compound and gives hospitals more leeway in how they store and transport supplies.
Peramivir’s structure allows for certain modifications at the acyl and guanidine positions. Researchers tested analogs with subtle shifts—such as different side chains—to check for broader activity against resistant strains. Some experiments involved esterifying the carboxyl group or tweaking the cyclopentane ring, but these changes often came at the cost of bioavailability or enzyme affinity. Although new analogs sometimes improved solubility, the clinical performance rarely surpassed the original, cementing peramivir as the gold standard from its chemical class.
Peramivir trihydrate is best known internationally as Rapivab in North America and Rapiacta in Japan. Pharmacopoeias, clinical trial reports, and patents reference its INN (International Nonproprietary Name) as peramivir, or cite synonyms like BCX-1812, reflecting its original research label. Hospital inventories may log it under any of these monikers, but the compound structure and CAS registry number—1041434-82-5—always point to the same molecule.
Strict protocols surround the handling and administration of peramivir trihydrate in clinical settings. Health workers wear gloves, check patient histories for allergies, and use filtered needles during reconstitution. Ready-for-use vials go straight from refrigeration to IV within set time limits. Institutional infection control guidelines spell out precise disposal methods for unused drug and contaminated materials to prevent both accidental exposure and environmental contamination. Hospitals often audit their process to catch any slips and update staff whenever new adverse event data surfaces.
Most peramivir leaves storage rooms during flu season surges, particularly in intensive care units and emergency departments. It works for both adults and children with confirmed or suspected influenza, especially where inhaled or oral routes fall short. Some regions keep it on hand for public health emergencies or outbreaks in long-term care, where rapid containment matters. Doctors also consider it in cases of antiviral resistance, since laboratory data confirms activity against many strains that evade older drugs.
After the initial breakthrough, research kept up a steady pace. Clinical trials in Asia, Europe, and North America nailed down optimal dosing and clarified benefit-risk balance. Investigators ran head-to-head studies versus oseltamivir, tracking time-to-resolution of symptoms and side-effect patterns. Animal models—ferrets, mice, and guinea pigs—helped uncover how peramivir worked in severe pneumonias, coinfection with other viruses, and special populations like the immunocompromised. Newer work focuses on resistance mechanisms, alternative delivery forms—like inhalation for outpatient use—and synergistic effects with other antivirals.
Safety trials demonstrated a margin between therapeutic and toxic doses, though rare cases of neuropsychiatric effects and hypersensitivity raised red flags. Animal studies flagged some concern about kidney function at very high exposures. Most clinical side effects remain mild or moderate, with diarrhea and injection site reactions at the top of the list. Pharmacovigilance data from real-world use gets pooled globally, letting researchers pick up on less common complications and share their findings with regulatory bodies to update protocols in real time.
Peramivir trihydrate stands poised for more than just incremental upgrades. With flu strains evolving and pandemic risk always present, there’s room on the research bench for improved analogs, long-acting injectables, and co-formulations with drugs targeting viral proteins outside neuraminidase. Next-generation sequencing and AI-driven drug design might point to molecules able to bypass resistance mutations that occasionally trouble today’s line-up. As more countries look for rapid-response tools against viral threats, hospitals and public health agencies will likely lean on peramivir trihydrate whenever speed and reliability are non-negotiable.
Seasonal flu can hit hard, especially for kids, older adults, and people who don’t bounce back quickly. Many people know about oseltamivir and zanamivir, but another player sometimes shows up in serious cases: peramivir trihydrate. Doctors prescribe this compound when flu symptoms need a fast, strong approach. Unlike pills or inhalers, peramivir gets delivered straight into the bloodstream by IV. That’s not a daily routine for most flu sufferers, but hospitals use it when swallowing medicine or using inhalers isn’t an option or isn’t working.
Most healthy folks manage the flu with rest, fluids, and patience. People who get very sick or land in the hospital deal with much higher risks, including the chance the virus overwhelms their system. Peramivir trihydrate, sold under the brand name Rapivab in the United States, steps into those high-risk situations. The U.S. Food and Drug Administration (FDA) approved this antiviral for adults and some school-age children with uncomplicated flu. Its value grows when patients cannot take oral medications or inhaled treatments.
Quick action matters when fighting viruses. Research shows that peramivir interrupts the spread of the virus inside the body by blocking an enzyme called neuraminidase. Disabling this enzyme slows down viral replication. With peramivir trihydrate, doctors can deliver a strong, one-time dose right into the bloodstream to get ahead of worsening symptoms. One of the writers here once saw this approach firsthand with a family member who could not swallow pills during a severe flu episode. In that hospital moment, the directness of peramivir made a tangible difference.
Every medication carries trade-offs. Peramivir does its job best in the early days of flu symptoms, usually within 48 hours. Administering it too late weakens its impact. Like other antivirals, peramivir does not cure the flu or substitute for vaccination. The drug can shorten the length of illness and might protect against complications in vulnerable people, but it does not work for every flu strain or every patient. Medical staff watch for possible side effects, such as skin reactions, diarrhea, and in rare cases, changes in behavior, especially in younger patients.
There’s always talk about fighting viruses without overusing powerful drugs. Widespread use of any antiviral, even one reserved for severe cases like peramivir, adds pressure that can lead to drug resistance over time. As more resistant flu viruses appear, the tools we rely on lose their edge. Doctors do not hand out peramivir lightly, understanding it should stay as a backup for high-need situations.
Staying informed about medications helps people ask better questions in the doctor’s office. Relying on flu vaccines builds a wall that protects whole communities, keeping demand for antivirals low. Supporting research for new drugs, staying updated on resistance trends, and using what works — not what’s simply available — all help slow the march of severe flu seasons. Behind every dose of peramivir trihydrate stands the reality that hospitals, families, and researchers want to keep the sharpest tools ready for those who need them most.
Peramivir Trihydrate gives doctors a strong weapon to fight influenza. It’s a prescription-only antiviral that works by blocking an enzyme flu viruses rely on to spread in the body. Doctors reach for it when pills or inhaled medicines just don’t fit the situation—typically when a patient has trouble swallowing or faces severe illness.
Hospitals run on the certainty of clear protocols. For a tough flu case, timing and reliable delivery decide outcomes. Peramivir Trihydrate only comes as an intravenous solution—something that demands skilled hands, clinical judgment, and logical infection-control measures. Health professionals mix the medication with sterile saline, then run it through a vein using a slow “drip,” allowing the medicine to head straight into the bloodstream without getting sidetracked by an upset stomach or slowed digestion. For adults and many children, a single dose usually does the trick. Sometimes unusual complications or poor response mean they call for more than one round.
Intravenous treatment isn’t overkill; it’s practical medicine for those who can't take drugs by mouth or whose illness stops their gut from working as it should. During my time volunteering in a hospital, I watched nurses double-check labels and lines, always wary of dosing errors and allergic reactions. One nurse told me the IV route isn’t just about effective drug levels—it guards against uncertainty. Nurses chart every dose, watch for signs of drug intolerance, and avoid mixing with fluids known to cause trouble.
While the science behind peramivir looks solid, the reality in emergency wards can get tricky. Hospitals can struggle with staff shortages. One busy season, flu cases filled nearly every room, and the guys and gals on the clock juggled IV medications non-stop. IV drugs mean extra monitoring, and any delay in getting an IV started can push treatment hours behind schedule. Patients allergic to any medication have to be watched even more closely, with nurses ready to handle a rare but dangerous reaction.
There’s also cost and access to think about. Some hospitals don’t keep peramivir stocked because it's used less often than oral flu drugs. In smaller clinics, delays in delivery mean patients might not see the benefit in time. Doctors then weigh risks and benefits fast—sometimes going with a different route simply because it’s on hand.
Faster diagnosis at the point of care means patients who truly need intravenous therapy can get it before complications rise. Investment in training keeps nurses and pharmacists prepared for rare drugs and scenarios, limiting mistakes and boosting care. Updated hospital inventory systems help pharmacists track medicines so doctors avoid guessing games about drug stock.
Manufacturers play a part, too. Smaller, ready-to-use vials cut down on preparation time. Clearer dosing instructions help all staff work with confidence, even in the busiest flu season. From emergency rooms to rural clinics, solid teamwork between pharmacy, nursing, and medical leads keeps patients safer and gets them on the mend faster.
Peramivir trihydrate turned up on the scene as a big name in treating the flu—especially for those times when swallowing pills seems impossible. It comes through as an intravenous drug, giving doctors a way to fight back when patients are knocked flat. But, like with any powerful tool, there are trade-offs. Knowing these matters—not just for doctors or pharmacists, but for anyone who ever faces a tough bout of influenza.
Every drug packs a list of possible side effects, and most people learn early to check for those unusual symptoms that pop up after starting a new treatment. With peramivir trihydrate, patients often mention feeling queasy. Nausea tops the list, and vomiting follows close behind. Researchers spotted diarrhea showing up on a regular basis, too. Sometimes, these symptoms hit hard enough to keep people from finishing a meal or getting out of bed, especially if they’re already sick from the flu.
Some folks also describe a mild fever creeping in after the infusion, or muscle aches that seem to stretch longer than regular flu symptoms. Throat pain and cough may stick around, sometimes making it tough to tell where the virus ends and the medication’s impact begins. For most, these effects pass as the drug clears their system. But the discomfort turns up in clinics often enough to stay on the radar.
Of course, not everyone sails through without problems. A handful of cases involve allergic reactions. Skin rashes, hives, and even tightness in the chest make appearances in rare patients. For those with allergies or sensitivities, that risk weighs heavier. Hospitals keep medications close by to treat these reactions if they happen.
Scientists have tracked rare reports of issues with liver function. Blood tests reveal high levels of liver enzymes. Most people never notice a difference, but those numbers tell doctors everything they need to know about what’s going on beneath the surface. Renal problems can also develop, especially in older adults or people with existing kidney concerns. Close monitoring helps catch these changes early.
Another concern floats around mental changes. Some adults and children mention confusion, strange behavior, or even hallucinations, though it’s tough sometimes to separate these from serious flu, high fevers, or dehydration. Japanese health officials raised alarms after some flu drugs caused neuropsychiatric side effects in younger patients, so it pays to watch anyone behaving out of character during treatment.
In my own family, a course of aggressive antivirals led my aunt to spend several days confused, convinced her childhood cat had returned. At the time, we chalked it up to high fever. Later, her doctor explained that the medication likely played a part. Stories like hers remind me that medications do more than fight disease—they reshape the whole experience.
Doctors weigh benefits and risks with each decision. The flu can turn deadly in the elderly or immunocompromised, and for those people, the promise of peramivir trihydrate overshadows the chance of a few days of discomfort. For others, especially those with sensitive systems or complex medical histories, conversations about these risks move to the front of the line.
Smart medicine rests on good conversations. Patients who speak up about their medical history—especially allergies and past reactions—set themselves up for safer care. Routine lab tests become even more important for those with liver or kidney conditions. By tracking symptoms daily, families and providers can catch complications early, long before they grow into bigger problems. Doctors keep alternatives in their toolkit, ready for people whose side effects climb out of the “normal” range.
Flu season brings enough misery without extra surprises. Peramivir trihydrate offers a way out for those hit hardest, but respect for its side effects turns a shot in the arm into a better, safer deal for everyone involved.
Peramivir trihydrate rolls off the tongue about as well as a marble, but this antiviral actually means a lot for people facing serious bouts of influenza. Hospitals often rely on it to tackle hard-hitting flu in adults who can't swallow pills or keep oral medicine down. So, with flu season knocking, parents and soon-to-be moms want to know: is peramivir trihydrate safe for their kids, or during pregnancy?
Hospitals in the United States received the FDA nod to use peramivir in treating kids two years and older for influenza. Real-world experience often starts in emergency rooms, not just textbooks. I’ve seen pediatric doctors push for options when fevers spike and a child can’t hold down Tamiflu. Peramivir, given by IV, gives hope for quick action.
Experts build these approvals from studies. d the numbers, most side effects—like diarrhea or skin reactions—parallel what you’d see with other flu meds. The main difference? Everything happens under hospital staff’s eyes. Years of CDC reporting flag no surprises, but parents need honest talks with doctors. Kids under two? The answer still sits at “no, not recommended” because safety data drops off fast for this crowd. Young bodies handle medicine differently, and tiny livers don’t process everything the way older children’s do.
No parent wants to risk the health of their unborn baby. Peramivir sits in a tricky spot here. The FDA placed it under “Category C,” which means animal studies saw some risk to the fetus, and there simply aren’t enough studies on actual pregnant women. That fact stops most prescribers from handing it out routinely. The CDC does note that a dangerous flu in pregnancy poses real threats to both baby and mom, from high fevers to breathing problems.
Major health bodies recommend Tamiflu (oseltamivir) as the first choice for pregnant women since more safety data supports its use. In rare emergencies—say, no response to other drugs or no other options with a severe case—doctors sometimes reach for peramivir and document everything. No evidence suggests massive outbreaks of birth defects, but without more research, most docs stay cautious. I’d want the same for my loved ones.
Parents and pregnant women deserve the best protection against the flu, but also protection from rare medication risks. The best path often starts with preventing influenza through vaccination, since flu can spiral out of control for these groups. If illness strikes and peramivir shows up as an option, open conversations matter. Let your doctor explain hospital experience, latest studies, and your family’s unique health needs. Science marches forward through careful research and transparency, not shortcuts or wishful thinking.
Big gaps in data prompt us to push for more pediatric and maternal research, not just settle for what works in adults. Asking questions, demanding careful monitoring, and reporting any unexpected reactions helps the whole community—patients, researchers, and families learning to trust hospital care all over again.
Peramivir trihydrate stands out as an antiviral, especially during flu seasons when the hospital wards fill up with folks fighting hard to breathe. It gets prescribed as an emergency solution for severe flu. Not everyone who gets the flu shot needs a punch from peramivir, and jumping right into its use can mean trouble for someone not in the right condition.
For one thing, the kidneys do a good deal of the work clearing this drug from the body. Folks with kidney issues, especially older adults, can get hit harder by side effects. Dosing has to be spot on—no guesswork. A nephrologist I trust told me about a patient whose kidneys slowed down after a rough bout of flu, and he ended up with more drug in his system than his body could shake. Doctors had to back off on the dose and watch for signs of trouble like confusion and irregular heartbeat. Without close monitoring, that story could have ended a lot worse.
Nausea, diarrhea, and even a rash sometimes turn up. That’s hardly all. I’ve watched folks have seizures and feel real mental confusion after getting this drug. Allergic reactions hit hard and fast—I mean hives, swelling, throat tightness, everything you don’t want late at night in a hospital. The FDA flagged rare but real neuropsychiatric effects, especially Children and teens have acted out with delirium or agitation.
Taking care with this drug isn’t just protocol, but common sense. Never take peramivir at home without a nurse or doctor nearby. The infusion route means someone should watch that vein. A nurse told me about catching a patient mid-infusion, sporting new flushed skin and swollen lips. The nurse pressed pause, got the emergency kit, and called for help. Quick action made all the difference. Skipping this kind of vigilance courts disaster.
Pregnant and breastfeeding women don’t fit into the standard playbook. Data just isn’t strong enough to call it safe in those cases. A trusted teacher always said, “Don’t be the first or second,” when it comes to exposing an unborn child to a new medicine. It’s wise to hold back unless the threat from flu overshadows any medicine risks. No one should mix peramivir with over-the-counter cold remedies, painkillers, or herbal supplements before asking a pharmacist. You’d be surprised how often the smallest pill triggers something unintended in the body.
Doctors, patients, pharmacists, and family all play a role. Patients who’ve had problems with allergic reactions in the past should say so early on—no detail too small. Medication lists, including those “natural” ones, deserve a place in the conversation. Keeping a log of how the patient feels after treatment can make a difference. If confusion, seizures, or new behavior changes show up, caregivers need to speak up fast. Letting those things rest for a day or two can mean turning a manageable side effect into a full-blown emergency.
Safe use comes down to active checks, honest talk, and knowing this isn’t a cure-all. Peramivir may save lives in the bleakest days of flu season, but it only works as part of a close partnership between patient and healthcare team. Respect for its power, and its risks, serves everyone under the same roof.
| Names | |
| Preferred IUPAC name | (1S,2S,3S,4S)-3-[(1R)-1-(Hydroxyacetyl)-2-oxopyrrolidin-3-yl]-4-(hydroxymethyl)-2-methoxy-3,4-dihydro-2H-pyran-5-carboxylic acid trihydrate |
| Other names |
BCX-1812 Biocryst 1812 Peramivir trihydrate (JAN/USAN/INN) Rapiacta RWJ-270201 |
| Pronunciation | /pə-ˈræm-ɪ-ˌvɪr traɪ-ˈhaɪ-dreɪt/ |
| Identifiers | |
| CAS Number | '389626-20-9' |
| Beilstein Reference | 4180409 |
| ChEBI | CHEBI:134724 |
| ChEMBL | CHEMBL2108705 |
| ChemSpider | 174704 |
| DrugBank | DB06612 |
| ECHA InfoCard | The ECHA InfoCard of product Peramivir Trihydrate is **"100000015021"**. |
| EC Number | 162426-91-1 |
| Gmelin Reference | 1628783 |
| KEGG | D09964 |
| MeSH | D000067345 |
| PubChem CID | 11450042 |
| RTECS number | OF3N3MSQ1J |
| UNII | 3K16G6ZZ5Q |
| UN number | UN3272 |
| Properties | |
| Chemical formula | C15H28N4O8·3H2O |
| Molar mass | 410.44 g/mol |
| Appearance | White to off-white crystalline powder |
| Odor | Odorless |
| Density | 1.62 g/cm³ |
| Solubility in water | Slightly soluble in water |
| log P | 0.1 |
| Acidity (pKa) | 13.84 |
| Basicity (pKb) | 8.4 |
| Magnetic susceptibility (χ) | -13.2e-6 cm³/mol |
| Dipole moment | 2.98 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 576.5 J·mol⁻¹·K⁻¹ |
| Pharmacology | |
| ATC code | J05AH02 |
| Hazards | |
| Main hazards | Harmful if swallowed. Causes serious eye irritation. |
| GHS labelling | GHS07, GHS08 |
| Pictograms | GHS05,GHS07 |
| Signal word | Warning |
| Hazard statements | Hazard statements: "H302: Harmful if swallowed. H315: Causes skin irritation. H319: Causes serious eye irritation. H335: May cause respiratory irritation. |
| Precautionary statements | P264, P270, P273, P301+P312, P330, P501 |
| Lethal dose or concentration | LD50 = >1,000 mg/kg (rat, oral) |
| LD50 (median dose) | LD50 (median dose): Mouse (intravenous): 500 mg/kg |
| NIOSH | Not Listed |
| PEL (Permissible) | Not Established |
| REL (Recommended) | 0.6 g |
| IDLH (Immediate danger) | ND |
| Related compounds | |
| Related compounds |
Oseltamivir Zanamivir Laninamivir Baloxavir marboxil |
